[L01AD04, streptozocin, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Streptozocin.]
[M04AX02, pegloticase, The therapeutic efficacy of Methoxy polyethylene glycol-epoetin beta can be decreased when used in combination with PEG-uricase.]
[L01BB02, mercaptopurine, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Mercaptopurine.]
[L02BA01, tamoxifen, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Tamoxifen.]
[L01CB02, teniposide, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Teniposide.]
[L04AX02, thalidomide, The risk or severity of thromboembolism can be increased when Thalidomide is combined with Methoxy polyethylene glycol-epoetin beta.]
[L01XX41, eribulin, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Eribulin.]
[L01AC01, thiotepa, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Thiotepa.]
[L01BB03, thioguanine, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Tioguanine.]
[L01XF01, tretinoin, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Tretinoin.]
[S01AD02, trifluridine, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Trifluridine.]
[L01FX04, ipilimumab, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Ipilimumab.]
[L01EX04, vandetanib, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Vandetanib.]
[L01AD08, uracil mustard, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Uracil mustard.]
[L02BX03, abiraterone, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Abiraterone.]
[L01CA01, vinblastine, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Vinblastine.]
[C04AX07, vincamine, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Vincamine.]
[L01CA02, vincristine, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Vincristine.]
[L01CA03, vindesine, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Vindesine.]
[L01EC01, vemurafenib, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Vemurafenib.]
[M05BA03, pamidronic acid, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Pamidronic acid.]
[L01FX05, brentuximab vedotin, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Brentuximab vedotin.]
[L01ED01, crizotinib, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Crizotinib.]
[L01XD05, temoporfin, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Temoporfin.]
[L01XX02, asparaginase, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Asparaginase Escherichia coli.]
[L04AA34, alemtuzumab, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Alemtuzumab.]
[L01EJ01, ruxolitinib, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Ruxolitinib.]
[L03AB11, peginterferon alfa-2a, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Peginterferon alfa-2a.]
[L01FA01, rituximab, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Rituximab.]
[L01XJ01, vismodegib, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Vismodegib.]
[L01EK01, axitinib, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Axitinib.]
[B03XA04, peginesatide, The therapeutic efficacy of Methoxy polyethylene glycol-epoetin beta can be decreased when used in combination with Peginesatide.]
[L01BC07, azacitidine, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Azacitidine.]
[L01BC05, gemcitabine, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Gemcitabine.]
[L01FX02, gemtuzumab ozogamicin, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Gemtuzumab ozogamicin.]
[L01FD02, pertuzumab, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Pertuzumab.]
[L01XG02, carfilzomib, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Carfilzomib.]
[L02BB04, enzalutamide, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Enzalutamide.]
[L01EA04, bosutinib, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Bosutinib.]
[L01EX05, regorafenib, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Regorafenib.]
[L01XL02, talimogene laherparepvec, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Talimogene laherparepvec.]
[L01AA09, bendamustine, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Bendamustine.]
[L01EX07, cabozantinib, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Cabozantinib.]
[L01EA05, ponatinib, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Ponatinib.]
[L04AX06, pomalidomide, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Pomalidomide.]
[L04AA18, everolimus, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Everolimus.]
[L01EC02, dabrafenib, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Dabrafenib.]
[L01EE01, trametinib, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Trametinib.]
[L01EB03, afatinib, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Afatinib.]
[L03AA14, lipegfilgrastim, The therapeutic efficacy of Lipegfilgrastim can be decreased when used in combination with Methoxy polyethylene glycol-epoetin beta.]
[L01EL01, ibrutinib, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Ibrutinib.]
[P01CX04, miltefosine, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Miltefosine.]
[L02BG02, formestane, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Formestane.]
[L04AC11, siltuximab, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Siltuximab.]
[L01ED02, ceritinib, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Ceritinib.]
[L01FG02, ramucirumab, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Ramucirumab.]
[L01XH04, belinostat, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Belinostat.]
[L01EM01, idelalisib, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Idelalisib.]
[L03AB13, peginterferon beta-1a, The therapeutic efficacy of Peginterferon beta-1a can be decreased when used in combination with Methoxy polyethylene glycol-epoetin beta.]
[L01FF02, pembrolizumab, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Pembrolizumab.]
[L01BC08, decitabine, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Decitabine.]
[L04AX05, pirfenidone, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Pirfenidone.]
[L01EX09, nintedanib, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Nintedanib.]
[L01FX07, blinatumomab, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Blinatumomab.]
[L01XK01, olaparib, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Olaparib.]
[L01FF01, nivolumab, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Nivolumab.]
[L01EF01, palbociclib, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Palbociclib.]
[L01EX08, lenvatinib, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Lenvatinib.]
[L01XH03, panobinostat, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Panobinostat.]
[L01DC01, bleomycin, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Bleomycin.]
[L01XJ02, sonidegib, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Sonidegib.]
[L01CX01, trabectedin, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Trabectedin.]
[L01EB04, osimertinib, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Osimertinib.]
[L01FC01, daratumumab, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Daratumumab.]
[L01EE02, cobimetinib, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Cobimetinib.]
[L01XG03, ixazomib, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Ixazomib.]
[L01FE03, necitumumab, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Necitumumab.]
[L01FX08, elotuzumab, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Elotuzumab.]
[L01ED03, alectinib, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Alectinib.]
[L01XA04, satraplatin, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Satraplatin.]
[L01XX52, venetoclax, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Venetoclax.]
[L01FF05, atezolizumab, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Atezolizumab.]
[L02AE01, buserelin, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Buserelin.]
[L01AB01, busulfan, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Busulfan.]
[L01XX27, arsenic trioxide, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Arsenic trioxide.]
[P01BE03, artesunate, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Artesunate.]
[L01FX10, olaratumab, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Olaratumab.]
[L01XK03, rucaparib, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Rucaparib.]
[L01EF02, ribociclib, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Ribociclib.]
[L01FF04, avelumab, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Avelumab.]
[L01XK02, niraparib, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Niraparib.]
[L01EX10, midostaurin, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Midostaurin.]
[L01FF03, durvalumab, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Durvalumab.]
[L01ED04, brigatinib, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Brigatinib.]
[P01AX10, fumagillin, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Fumagillin.]
[L01BC06, capecitabine, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Capecitabine.]
[L01XX59, enasidenib, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Enasidenib.]
[L01EH02, neratinib, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Neratinib.]
[L01FB01, inotuzumab ozogamicin, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Inotuzumab ozogamicin.]
[L01XH01, vorinostat, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Vorinostat.]
[L01EM02, copanlisib, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Copanlisib.]
[L01EF03, abemaciclib, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Abemaciclib.]
[L01BA03, raltitrexed, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Raltitrexed.]
[L01XL04, tisagenlecleucel, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Tisagenlecleucel.]
[L01XL03, axicabtagene ciloleucel, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Axicabtagene ciloleucel.]
[L02BB05, apalutamide, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Apalutamide.]
[A16AB19, pegvaliase, The therapeutic efficacy of Pegvaliase can be decreased when used in combination with Methoxy polyethylene glycol-epoetin beta.]
[L01EC03, encorafenib, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Encorafenib.]
[L01EE03, binimetinib, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Binimetinib.]
[L01XX62, ivosidenib, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Ivosidenib.]
[L01FX09, mogamulizumab, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Mogamulizumab.]
[L01EM04, duvelisib, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Duvelisib.]
[L01FF06, cemiplimab, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Cemiplimab.]
[L01EB07, dacomitinib, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Dacomitinib.]
[L03AX21, elapegademase, The therapeutic efficacy of Elapegademase can be decreased when used in combination with Methoxy polyethylene glycol-epoetin beta.]
[L01FB02, moxetumomab pasudotox, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Moxetumomab pasudotox.]
[L01XK04, talazoparib, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Talazoparib.]
[L01ED05, lorlatinib, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Lorlatinib.]
[L01AD01, carmustine, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Carmustine.]
[L01EX12, larotrectinib, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Larotrectinib.]
[L01EX13, gilteritinib, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Gilteritinib.]
[L01XJ03, glasdegib, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Glasdegib.]
[L01XX67, tagraxofusp, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Tagraxofusp.]
[L01EN01, erdafitinib, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Erdafitinib.]
[L01XX29, denileukin diftitox, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Denileukin diftitox.]
[L01EM03, alpelisib, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Alpelisib.]
[L01FX14, polatuzumab vedotin, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Polatuzumab vedotin.]
[L01XX66, selinexor, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Selinexor.]
[L02BB06, darolutamide, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Darolutamide.]
[L01EX15, pexidartinib, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Pexidartinib.]
[L01EJ02, fedratinib, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Fedratinib.]
[L01EX14, entrectinib, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Entrectinib.]
[L01FD01, trastuzumab, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Trastuzumab.]
[L01FD03, ado-trastuzumab emtansine, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Trastuzumab emtansine.]
[L01FD04, trastuzumab deruxtecan, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Trastuzumab deruxtecan.]
[L01EL03, zanubrutinib, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Zanubrutinib.]
[L01FX13, enfortumab vedotin, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Enfortumab vedotin.]
[L01XX10, masoprocol, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Masoprocol.]
[L01FC02, isatuximab, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Isatuximab.]
[L01EE04, selumetinib, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Selumetinib.]
[G03DB08, dienogest, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Dienogest.]
[L01XD01, porfimer sodium, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Porfimer sodium.]
[L01XF03, bexarotene, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Bexarotene.]
[L01AA02, chlorambucil, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Chlorambucil.]
[L01EN02, pemigatinib, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Pemigatinib.]
[L01FX17, sacituzumab govitecan, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Sacituzumab govitecan.]
[L01EH03, tucatinib, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Tucatinib.]
[L01EX17, capmatinib, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Capmatinib.]
[L01EX19, ripretinib, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Ripretinib.]
[L01EX22, selpercatinib, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Selpercatinib.]
[L01XX69, lurbinectedin, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Lurbinectedin.]
[L01FX12, tafasitamab, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Tafasitamab.]
[L01XL06, brexucabtagene autoleucel, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Brexucabtagene autoleucel.]
[L01DB04, aclarubicin, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Aclarubicin.]
[L01EX23, pralsetinib, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Pralsetinib.]
[G03CA06, chlorotrianisene, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Chlorotrianisene.]
[L01BB05, fludarabine, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Fludarabine.]
[L01FD06, margetuximab, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Margetuximab.]
[L01EX21, tepotinib, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Tepotinib.]
[L01EX25, umbralisib, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Umbralisib.]
[J01MB07, flumequine, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Flumequine.]
[S01LA08, bevacizumab, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Bevacizumab.]
[L01EK03, tivozanib, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Tivozanib.]
[L03AB10, peginterferon alfa-2b, The therapeutic efficacy of Methoxy polyethylene glycol-epoetin beta can be decreased when used in combination with Peginterferon alfa-2b.]
[L01XL07, idecabtagene vicleucel, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Idecabtagene vicleucel.]
[L01FF07, dostarlimab, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Dostarlimab.]
[L01FX22, loncastuximab tesirine, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Loncastuximab tesirine.]
[L01XX73, sotorasib, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Sotorasib.]
[L01EN03, infigratinib, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Infigratinib.]
[L01XA01, cisplatin, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Cisplatin.]
[L01XX74, belzutifan, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Belzutifan.]
[L01FX23, tisotumab vedotin, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Tisotumab vedotin.]
[L01EA06, asciminib, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Asciminib.]
[L02BG06, exemestane, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Exemestane.]
[L01XX75, tebentafusp, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Tebentafusp.]
[L01FX20, tremelimumab, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Tremelimumab.]
[L01XX77, adagrasib, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Adagrasib.]
[L01EN04, futibatinib, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Futibatinib.]
[L01FE02, panitumumab, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Panitumumab.]
[L01EX11, quizartinib, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Quizartinib.]
[L01XX40, omacetaxine mepesuccinate, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Omacetaxine mepesuccinate.]
[L01BB07, nelarabine, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Nelarabine.]
[H01AX01, pegvisomant, The therapeutic efficacy of Methoxy polyethylene glycol-epoetin beta can be decreased when used in combination with Pegvisomant.]
[L02BA03, fulvestrant, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Fulvestrant.]
[L01EA01, imatinib, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Imatinib.]
[L01AA01, cyclophosphamide, The risk or severity of pulmonary toxicity can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Cyclophosphamide.]
[L01BC01, cytarabine, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Cytarabine.]
[L01AX04, dacarbazine, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Dacarbazine.]
[L01DA01, dactinomycin, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Dactinomycin.]
[L01DB02, daunorubicin, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Daunorubicin.]
[L01DB09, valrubicin, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Valrubicin.]
[L02BB02, nilutamide, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Nilutamide.]
[L01FE01, cetuximab, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Cetuximab.]
[L01XA03, oxaliplatin, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Oxaliplatin.]
[S03BA01, dexamethasone, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Dexamethasone.]
[L01EB01, gefitinib, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Gefitinib.]
[L01DC04, ixabepilone, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Ixabepilone.]
[L01EB02, erlotinib, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Erlotinib.]
[L01DB08, pirarubicin, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Pirarubicin.]
[L03AA13, pegfilgrastim, The therapeutic efficacy of Methoxy polyethylene glycol-epoetin beta can be decreased when used in combination with Pegfilgrastim.]
[L01XX24, pegaspargase, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Pegaspargase.]
[L04AX04, lenalidomide, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Lenalidomide.]
[L01EX01, sunitinib, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Sunitinib.]
[L01XG01, bortezomib, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Bortezomib.]
[L01DB01, doxorubicin, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Doxorubicin.]
[L01AX03, temozolomide, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Temozolomide.]
[L02BA02, toremifene, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Toremifene.]
[L01AB02, treosulfan, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Treosulfan.]
[H02CA01, trilostane, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Trilostane.]
[L02AE04, triptorelin, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Triptorelin.]
[L01AA07, trofosfamide, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Trofosfamide.]
[L01CA04, vinorelbine, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Vinorelbine.]
[L01DB03, epirubicin, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Epirubicin.]
[L01XA02, carboplatin, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Carboplatin.]
[N03AG01, valproic acid, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Valproic acid.]
[L01XX11, estramustine, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Estramustine.]
[L01AG01, ethoglucid, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Etoglucid.]
[L01CB01, etoposide, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Etoposide.]
[J01MA08, fleroxacin, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Fleroxacin.]
[P01AX07, trimetrexate, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Trimetrexate.]
[L02AE02, leuprolide, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Leuprolide.]
[L01BB06, clofarabine, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Clofarabine.]
[L04AA40, cladribine, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Cladribine.]
[L01BC09, floxuridine, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Floxuridine.]
[L01BC02, fluorouracil, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Fluorouracil.]
[L02BB01, flutamide, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Flutamide.]
[L01BC03, tegafur, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Tegafur.]
[L02BX02, degarelix, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Degarelix.]
[L01EA02, dasatinib, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Dasatinib.]
[N04BC06, cabergoline, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Cabergoline.]
[L01EH01, lapatinib, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Lapatinib.]
[L01EX02, sorafenib, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Sorafenib.]
[S01LA03, pegaptanib, The therapeutic efficacy of Methoxy polyethylene glycol-epoetin beta can be decreased when used in combination with Pegaptanib.]
[L02AE03, goserelin, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Goserelin.]
[L01CE02, irinotecan, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Irinotecan.]
[L01XX03, altretamine, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Altretamine.]
[L01XX05, hydroxyurea, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Hydroxyurea.]
[L01DB06, idarubicin, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Idarubicin.]
[L01AA06, ifosfamide, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Ifosfamide.]
[L01CD01, paclitaxel, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Paclitaxel.]
[L01CD03, paclitaxel poliglumex, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Paclitaxel poliglumex.]
[L01CE01, topotecan, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Topotecan.]
[L03AB04, interferon alfa-2a, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Interferon alfa-2a.]
[L03AB05, interferon alfa-2b, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Interferon alfa-2b.]
[L01XX35, anagrelide, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Anagrelide.]
[L03AX04, pegademase bovine, The therapeutic efficacy of Methoxy polyethylene glycol-epoetin beta can be decreased when used in combination with Pegademase.]
[L01DC03, mitomycin, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Mitomycin.]
[L01AD02, lomustine, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Lomustine.]
[L01EG01, temsirolimus, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Temsirolimus.]
[L01BA05, pralatrexate, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Pralatrexate.]
[L01EA03, nilotinib, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Nilotinib.]
[L01AA05, mechlorethamine, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Mechlorethamine.]
[L01AA03, melphalan, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Melphalan.]
[L02BG01, aminoglutethimide, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Aminoglutethimide.]
[H01CB03, lanreotide, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Lanreotide.]
[L01XD04, aminolevulinic acid, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Aminolevulinic acid.]
[L01BA04, pemetrexed, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Pemetrexed.]
[L04AX03, methotrexate, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Methotrexate.]
[H02AB04, methylprednisolone, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Methylprednisolone.]
[G03EK01, methyltestosterone, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Methyltestosterone.]
[L01DC02, plicamycin, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Plicamycin.]
[L01AX01, mitobronitol, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Mitobronitol.]
[L01XX23, mitotane, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Mitotane.]
[L01DB07, mitoxantrone, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Mitoxantrone.]
[L03AA03, molgramostim, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Molgramostim.]
[L03AC01, aldesleukin, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Aldesleukin.]
[L04AB05, certolizumab pegol, The therapeutic efficacy of Methoxy polyethylene glycol-epoetin beta can be decreased when used in combination with Certolizumab pegol.]
[L04AA52, ofatumumab, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Ofatumumab.]
[L01EX03, pazopanib, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Pazopanib.]
[S01XA11, nandrolone, The therapeutic efficacy of Methoxy polyethylene glycol-epoetin beta can be increased when used in combination with Nandrolone phenpropionate.]
[L01CD02, docetaxel, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Docetaxel.]
[L02BG04, letrozole, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Letrozole.]
[L01XX01, amsacrine, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Amsacrine.]
[H01CB02, octreotide, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Octreotide.]
[J01MB05, oxolinic acid, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Oxolinic acid.]
[L01XX08, pentostatin, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Pentostatin.]
[L01FX01, edrecolomab, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Edrecolomab.]
[L01XF02, alitretinoin, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Alitretinoin.]
[L02BB03, bicalutamide, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Bicalutamide.]
[L01AX02, pipobroman, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Pipobroman.]
[L02BG03, anastrozole, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Anastrozole.]
[A06AD15, polyethylene glycols, The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Methoxy polyethylene glycol-epoetin beta.]
[L01AA08, prednimustine, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Prednimustine.]
[S03BA02, prednisolone, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Prednisolone.]
[H02AB07, prednisone, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Prednisone.]
[L01XB01, procarbazine, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Procarbazine.]
[L01XH02, romidepsin, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Romidepsin.]
[C05BB02, polidocanol, The therapeutic efficacy of Methoxy polyethylene glycol-epoetin beta can be decreased when used in combination with Polidocanol.]
[L01FA03, obinutuzumab, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Obinutuzumab.]
[L01CD04, cabazitaxel, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Cabazitaxel.]
